• News
  • Atriva Therapeutics Receives EU Award for Biomarker Validation

Invited keynote lecture on ATRIVAs antiviral MEK inhibitor technology presented at the Annual Meeting of the German Pharmaceutical Society (DPhG)

Atriva scientists were invited to give a keynote lecture on their antiviral MEK inhibitor concept at the Annual Meeting of the German Pharmaceutical Society (DPhG).

The meeting entitled „Novel Therapies for Future Challenges“ was held from September 26 – 29, 2017 at Saarland University, Saarbrücken, Germany.

The talk entitled "Repurposing of Kinase Inhibitors to Fight the Flu –MEK Inhibitors Efficiently Block Influenza Virus Replication in Mice with a Prolonged Therapeutic Window" was presented on September 28th, 2017 as one of three keynote presentations in the session "Antiviral Therapy". You can download the abstract here.


Atriva Therapeutics GmbH
Christophstr. 32, 72072 Tübingen

+49 (0)7071 8597673

In order to be able to design our website in the best possible way and to continuously improve it, we are using cookies. By continuing to use our website, you permit the use of cookies. More information can be found in our data protection rules.
Data Protection Rules I Agree